地舒單抗，Denosumab，CAS:615258-40-7，AntibodySystem Laboratories

貨號：DHA30301

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75128.html

別名：AMG162, CAS: 615258-40-7

簡介：

Denosumab 是一種人單克隆抗體，結(jié)合并抑制 RANKL 受體激活因子 (TNFSF11)。Denosumab 可以降低椎骨、非椎骨和髖部骨折的風(fēng)險，也具有抗癌活性。

貨號DHA30301

產(chǎn)品品牌：Antibodysystem

通用名：Denosumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：AMG162

靶點;物種：Human CD254/RANKL/TNFSF11

種類：Homo sapiens

受體鑒定：IgG2-kappa

CAS: 615258-40-7

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻：

Stopping Denosumab. PMID: 30659428

Denosumab: A Review in Postmenopausal Osteoporosis. PMID: 29435849

Denosumab versus romosozumab for postmenopausal osteoporosis treatment. PMID: 34083636

A Review on the Role of Denosumab in Fracture Prevention. PMID: 33061307

Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. PMID: 25639776

Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. PMID: 28789921

Treatment of fibrous dysplasia: focus on denosumab. PMID: 34964677

Denosumab Discontinuation. PMID: 36564572

Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review. PMID: 35059777

Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. PMID: 34849989

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. PMID: 33813753

Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. PMID: 31776637

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases. PMID: 34009703

Denosumab: AHFS 92:24. PMID: 29864491

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. PMID: 30071889

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature. PMID: 35417954

Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. PMID: 27862983

Denosumab in osteoporosis. PMID: 24289327

Denosumab for dialysis patients with osteoporosis: A cohort study. PMID: 32051451

Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. PMID: 30535289

Denosumab cessation. PMID: 32487553

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. PMID: 29573473

Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. PMID: 31616133

Denosumab Use in Adults With Fibrous Dysplasia: Case Reports and Review of the Literature. PMID: 35952985

Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. PMID: 31678488

Denosumab in the treatment of glucocorticoid-induced osteoporosis. PMID: 30019224

Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits. PMID: 33616817

Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials. PMID: 34383097

Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. PMID: 32333877

Denosumab: an Emerging Therapy in Pediatric Bone Disorders. PMID: 28643220

Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial. PMID: 30690785

Denosumab for Reducing Risk of Fractures in Postmenopausal Women. PMID: 31038897

Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. PMID: 35362725

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. PMID: 28539165

Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. PMID: 32716706

Denosumab, an effective osteoporosis treatment option for men. PMID: 36068715

Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis. PMID: 32964403

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. PMID: 29694685

Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study. PMID: 35032187

Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report. PMID: 35173680

Treatment of Hypercalcemia of Malignancy. PMID: 34774248

Effects and management of denosumab discontinuation. PMID: 29317292

Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis. PMID: 34111556

Long-term consequences of osteoporosis therapy with denosumab. PMID: 36382761

Hypercalcemia of Malignancy. PMID: 34774243

Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature. PMID: 30644830

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation. PMID: 36201122

Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. PMID: 29616561

Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial. PMID: 32459005

Trends of denosumab-related publications in web of science. PMID: 36705356

Denosumab: a new agent in the management of hypercalcemia of malignancy. PMID: 26403973

Denosumab and muscle performance. PMID: 36378303

The role of neoadjuvant denosumab in the treatment of aneurysmal bone cysts: a case series and review of the literature. PMID: 36282899

The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. PMID: 33287586

COVID pandemic and denosumab adherence. PMID: 35066593

Short or Long-term Osteoporosis Therapy With Denosumab? PMID: 34561999

Denosumab increases spine bone density in women with anorexia nervosa: a randomized clinical trial. PMID: 36134902

Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. PMID: 27120345

Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone. PMID: 32623530

Off-label uses of denosumab in metabolic bone diseases. PMID: 31454537

Certainties and Uncertainties About Denosumab Discontinuation. PMID: 29926143

Effects of Denosumab After Treatment Discontinuation : A Review of the Literature. PMID: 29720299

Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report. PMID: 34232341

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. PMID: 30508316

Denosumab Use in Rats: Letter to the Editor. PMID: 36749803

Denosumab and lichen planus: two cases. PMID: 32656848

Denosumab after 8 years. PMID: 26475285

Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. PMID: 33057735

Romosozumab and antiresorptive treatment: the importance of treatment sequence. PMID: 35165774

[The problem of withdrawal denosumab treatment]. PMID: 35177336

A comprehensive review of denosumab for bone metastasis in patients with solid tumors. PMID: 26451465

How safe and effective is denosumab for bone giant cell tumour? PMID: 28646421

Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery. PMID: 35175454

Questions and facts regarding denosumab discontinuation among postmenopausal women. PMID: 33372551

Osteoporosis Therapeutics 2020. PMID: 32767142

Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia. PMID: 35641572

Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial. PMID: 33975993

[Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?]. PMID: 29871576

The current standing on the use of denosumab in giant cell tumour of the bone. PMID: 33331233

[Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone]. PMID: 27593237

Denosumab in Prevention of Implant Migration. PMID: 32609393

Adjuvant denosumab in early breast-cancer. PMID: 32135107

Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review. PMID: 32661185

Denosumab is not associated with risk of malignancy? More evidence is needed. PMID: 34383098

Analysis of denosumab on skeletal-related events in patients with advanced breast cancer. PMID: 26414586

Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature. PMID: 30826108

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis. PMID: 26554766

Adjuvant denosumab in early breast cancer. PMID: 32135106

Delayed Denosumab Injections and Fracture Risk. PMID: 32716699

Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction. PMID: 35272085

Cardiovascular Safety of Denosumab Across Multiple Indications. PMID: 33095450

Palliative Oncology: Denosumab. PMID: 24928835

Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review. PMID: 26639186

Cancel the denosumab holiday. PMID: 26932443